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A B S T R A C T
Purpose: To examine adult epilepsy outpatients for the existence of the interictal dysphoric disorder
(IDD) using the interictal dysphoric disorder inventory (IDDI), the overlap between IDD, depression, and
anxiety, and the reproducibility of IDDI.
Methods: Epilepsy outpatients were assessed with the Danish IDDI and self-report inventories for
depression and anxiety. Patients with abnormal scores were further assessed with the Mini International
Neuropsychiatric Interview (MINI). Patients with IDD were asked to repeat IDDI for evaluating the
reproducibility. Quality of life, well-being and adverse effects to antiepileptic drugs were determined.
Results: We included 169 patients, and 32 (19%) were diagnosed with IDD. Thirty patients were further
assessed with MINI, and 17 (57%) were diagnosed with additional psychiatric disorders, mainly
depression, dysthymia, and anxiety. Patients with IDD and additional psychiatric comorbidity had
signiﬁcantly higher seizure frequency, higher level of side effects to the antiepileptic treatment, and
lower quality of life, both when compared to patients with normal screening and patients with IDD as the
only comorbidity. The reproducibility of the Danish IDDI was only 50%.
Conclusion: With a prevalence of 19%, IDD appeared to be the commonest neuropsychiatric syndrome.
The majority of the patients with IDD also had depressive and/or anxiety disorders. Quality of life, seizure
control, and side effects to antiepileptic drugs were affected much more by depression or anxiety, than
by IDD. The Danish version of IDDI has a poor reproducibility. The existence of IDD as a diagnostic entity
is doubtful.
 2014 The Authors. ISDN. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Contents lists available at ScienceDirect
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Since the time of Hippocrates, associations between epilepsy
and depression have been described.1 In German psychiatric
literature, a depressive condition with special characteristics in
epilepsy patients has been described by Kraepelin2 and
Bleuler.3 This condition was characterized by affective symp-
toms including irritability and euphoria as speciﬁc symptoms.
Others have conﬁrmed that a considerable fraction of epilepsy
patients have this long lasting condition, and Blumer described
this Interictal Dysphoric Disorder (IDD) as a condition charac-
terized by labile depressive symptoms, labile affective symp-
toms, and the speciﬁc symptoms euphoria and paroxysmal
irritability.4,5
In the literature on the psychiatric aspects of epilepsy, there is
disagreement as to the existence of IDD. Mula et al. have* Corresponding author. Tel.: +45 29 37 31 21; fax: +45 48 29 38 72.
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nd/3.0/).investigated the features of IDD, and they argue that such a
syndrome exists as a homogenous construct with speciﬁc clinical
features.1,6,7 However, IDD does not seem to be speciﬁc for
epilepsy, as it is also diagnosed in patients with migraine.6
It is now possible to diagnose IDD with the self-report
inventory, the Interictal Dysphoric Disorder Inventory (IDDI).1
According to the published criteria, the diagnosis IDD requires
that at least three of the following symptoms of moderate/severe
severity leading to moderate/severe limitation have been present
in the previous 12 months: anergia, pain, sleeplessness, fear/panic,
anxiety, depression, euphoria, and irritability. Using the IDDI, it was
the purpose of the present study to examine the existence of IDD in
a population of epilepsy outpatients. Consequently, we translated
IDDI from English to Danish.8 The reliability of the IDDI was
assessed by repeating the use of the IDDI in the same epilepsy
patients. Since the time frame of the IDDI is 12 months, a high
degree of reproducibility was expected. To further investigate the
existence of IDD as a nosological entity we assessed the occurrence
of the speciﬁc IDD symptoms euphoria and paroxysmal irritability
in patients with and without IDD.rticle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
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2.1. Subjects
Adult patients with epilepsy treated at the epilepsy outpatient
clinic, Department of Neurology, University Hospital of North
Zealand were included from January 1 to December 31, 2013. The
inclusion criteria were as follows: age 18 years or above, diagnosis
of epilepsy according to criteria by the International League Against
Epilepsy, MRI or CT scan of the brain, EEG, treatment with at least
one AED in a constant dose in the previous month, and the ability to
read and speak Danish. Exclusion criteria were severe medical or
psychiatric comorbidity and inability to read and speak Danish.
2.2. Flow of patients
All patients received oral and written information. After
informed consent to participate in the study, the patients were
given the following self-report inventories:
 Anxiety Symptom Scale (ASS)
 Major Depression Inventory (MDI)
 Neurological Disorder Depression Inventory for Epilepsy
(NDDI-E)
 Quality of Life in Patients with Epilepsy (QOLIE-31)
 World Health Organization Well-being Index (WHO-5)
 Liverpool Adverse Events Proﬁle to antiepileptic drugs (LAEP)
 Interictal Dysphoric Disorder Inventory (IDDI)
If patients scored above threshold in ASS, MDI, or NDDI-E or
fulﬁlled the criteria for IDD, a Mini International Neuropsychiatric
Interview version 5.0.0 (MINI) was carried out.9 Patients diagnosed
with depression or anxiety were assessed with the Hamilton
Depression Scale (HAM-D17)10 and the Hamilton Anxiety Scale
(HAM-A14),10 respectively, to measure disease severity. Patients,
who were diagnosed with a psychiatric disorder, were offered
treatment according to local practice. To test the reproducibility of
the Danish version of IDDI, all patients who underwent MINI, were
asked to complete the IDDI again. This retest took place from 4 to
11 weeks after the ﬁrst IDDI.
2.3. Translation of IDDI, NDDI-E and LAEP to Danish
IDDI, NDDI-E, and LAEP did not exist in Danish before this study.
These three inventories were translated from English to Danish
according to published methods.8 First, a neurologist and a
psychiatrist, both ﬂuent in English and Danish, independently
translated the three inventories. Consensus was found, and the
three inventories were sent to a professional Danish–English
translator who carried out a back-translation of the Danish
versions to English. Finally, a Danish–English language specialist
from the Research Unit at the Copenhagen University Psychiatric
Centre of North Zealand carried out a debrieﬁng of the results of the
translation-back-translation procedures, and a few corrections
were made. The adjusted translations were tested by the language
specialist on three patients before use in the study to assure that
the questions were clearly understood in the same way as they
were written in the English versions. The Danish versions of these
inventories are available as appendices.
2.4. The Major Depression Inventory (MDI)
The scale contains the items that cover the ICD-10 symptoms of
depression. We used the MDI as a diagnostic tool requiring core
symptoms of depression to be present most of the time for the past
two weeks.112.5. The Anxiety Symptom Scale (ASS)
The ASS consists of 10 items. The presence of the items on levels
0–5 in the previous 14 days is assessed. The ASS was considered
positive when Item 10, the impact on daily activities, had a score of
three or more, and there was a score on the top three symptoms
which are the actual anxiety symptoms.10
2.6. The Neurological Disorder Depression Inventory for Epilepsy
(NDDI-E)
This screening tool for depression was developed for use
speciﬁcally in patients with epilepsy. It consists of six statements
about the past two weeks that are scored between 1 (never) and 4
(always/often), with a minimum score of 6 and maximum of 24. In
the original version, a score above 15 has been shown to have high
predictive value for major depression.12
2.7. The Interictal Dysphoric Disorder Inventory (IDDI)
This self-report questionnaire is speciﬁcally developed to
diagnose IDD and to evaluate IDD symptoms in terms of presence,
frequency, severity, and global impairment in the previous 12
months. Eight symptoms are examined. They are grouped into
labile depressive symptoms (anergia, depressed mood, insomnia,
and pain), labile affective symptoms (anxiety and fear), and
speciﬁc symptoms (euphoric moods and paroxysmal irritability.
The diagnosis of IDD is deﬁned by the presence of at least three
symptoms of ‘‘moderate’’ or ‘‘severe’’ severity and causing
‘‘moderate’’ or ‘‘severe’’ distress.1
The IDDI also includes an appendix with questions regarding
the temporal relationship of the different IDD symptoms and their
relations to seizures. In this study, we have chosen not to use the
appendix, since it is not required for the diagnosis of IDD.
Furthermore, many of our patients found the appendix too difﬁcult
to answer.
2.8. The Liverpool Adverse Events Proﬁle (LAEP)
The LAEP is a 20-item self-report inventory for adverse events
to antiepileptic drugs. These items are rated by the patient from
one (the symptom is never a problem) to four (the symptom is
always or often a problem).13
2.9. The World Health Organization Well-being Index (WHO-5)
The WHO-5 consists of ﬁve items. Each item is rated on a 6-
point scale from 0 to 5. The score ranges from 0 to 25. The
percentage value is calculated by multiplying the score by 4 and
thus obtaining a scale from 0 (worst) to 100 (best). A percentage
score below 50 is interpreted as indicating risk of depression and
anxiety.10
2.10. The Quality of Life in Epilepsy Inventory (QOLIE-31)
The QOLIE-31 consists of seven multi-item scales. An overall
score of 50 is the average for persons with epilepsy. The t-score
ranges from 11 to 73.14
2.11. The Mini International Neuropsychiatric Interview version 5.0.0
(MINI)
The MINI-D is a Danish version of the Mini International
Neuropsychiatric Interview version 5.0.0 (MINI), a previously
validated interviewer-administered, structured, diagnostic
psychiatric interview for DSM-IV and ICD-10.9 In this study, the
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diagnosis in the participants with abnormal scores on MDI, ASS,
NDDI-E and IDDI.
2.12. Statistics
The results for epilepsy patients with psychiatric comorbidity
were compared with the results for epilepsy patients without
psychiatric comorbidity. We used SAS 9.3. Continuous data were
compared using unpaired t-tests. The Chi-square test was used for
categorical data, and Fisher’s exact test if the cells had a frequency
of ﬁve or less. P < 0.05 was considered statistically signiﬁcant.
2.13. Ethics
The study was approved by the Ethical Committee of the Capital
Region of Denmark (H-3-2012-086). All patients gave their written
informed consent prior to inclusion in the study.
3. Results
3.1. Basic characteristics of patients with IDD
A total of 176 patients were included in the study, and 169
returned the self-report inventories. Forty-two patients had a score
above threshold in at least one of the following inventories; IDDI,
MDI, ASS, and NDDI-E. IDD was found in 32 patients (19%), and 19
of these also scored above threshold in at least one of the other self-
report inventories screening for depression and anxiety (ASS, MDI
and NDDI-E). Table 1 shows the basic data for included patients.
3.2. Depression, anxiety and IDD
Of the 42 patients with abnormal scores, 39 underwent MINI.
Psychiatric disorder according to MINI was found in 23 patients
(14%), the majority (19 patients) being depression, dysthymia,
anxiety disorders, or a combination of these. The severity of
depression as assessed with the HAM-D17 was mild or moderate
(range 14–22), and the severity of anxiety as assessed by HAM-A14Table 1
Basic characteristics of patients with normal score after screening, patients with abnorm
Variable 
Subjects, n 
Age, mean years (SD) 
Female, n 
Epilepsy diagnosis, n
G40.1: epilepsy with simple focal seizures 
G40.2: epilepsy with complex focal seizures and secondarily generalized seizures 
G40.3: epilepsy with generalized seizures 
Others (G40.4, G40.5, G40.6, G40.9, R56,8) 





Treatment with two or more AEDs per Subject, n 
Presence of side effects according to the LAEP (score range 20–80) 
Treatment with antidepressant, n 
* Statistically signiﬁcant difference (P < 0.05) when compared to patients with normwas questionable to moderate (9–22). The distribution of patients
with psychiatric disorders according to MINI is seen in Fig. 1.
Of the 32 patients with IDD, 30 underwent MINI. Fig. 2 shows
the distribution of MINI veriﬁed psychiatric diagnosis in patients
with IDD.
According to MINI 13 patients with IDD did not fulﬁll the
diagnostic criteria for any psychiatric disorder. Depression was
found in eight patients, ﬁve patients had dysthymia, four had
anxiety, and four patients were diagnosed with other psychiatric
comorbidities than the above mentioned. All patients with IDD and
anxiety were also diagnosed with depression or dysthymia.
In total we found depression in 10 patients, of whom 8 also had
IDD, and dysthymia was diagnosed in 7 patients of whom 5 had
IDD. Thus, 13 (76%) of the patients with depressive disorders also
fulﬁlled the criteria for IDD.
In Table 2 patients with IDD are separated into two subgroups;
patients with IDD as the only neuropsychiatric disorder and
patients with IDD and an additional MINI veriﬁed psychiatric
diagnosis. The subgroups are compared to patients without IDD.
Patients with only IDD have more resemblance with patients
without IDD than with patients with IDD and a MINI-based
diagnosis. IDD patients with other psychiatric comorbidity were
less likely to be seizure free compared to epilepsy patients with
only IDD, and they were more likely to be treated with
antidepressants. These differences were statistically signiﬁcant.
3.3. Euphoria and irritability
Euphoria and paroxysmal irritability were considered to be
present if they were indicated in IDDI as ‘‘moderate’’ or ‘‘severe’’
and causing ‘‘moderate’’ or ‘‘severe’’ distress. Euphoria was found
in 1 out of the 13 patients with only IDD (7.7%) and 2 of 17 patients
with IDD and additional MINI veriﬁed diagnosis (11.8%). In patients
without any psychiatric comorbidity we found euphoria in 0.7%.
Paroxysmal irritability was found in 7 out of 13 patients with only
IDD (53.8%), 12 out of 17 patients with IDD and additional MINI
veriﬁed psychiatric comorbidity (70.6%) and in only 1.5% of
patients without any psychiatric comorbidity. The prevalence of
euphoria and paroxysmal irritability was signiﬁcantly higher inal scores, patients with IDD and patients with MINI veriﬁed psychiatric disorders.







127 (75%) 42 (25%) 32 (19%) 23 (14%)
55 (17.2) 46 (15.9)* 44 (15.4)* 48 (16.3)*
55 (43%) 27 (64%)* 22(68%)* 12 (52%)
8 (6%) 1 (2%) 1 (3%) 1 (4%)
86 (68%) 31 (74%) 23 (72%) 17 (74%)
15 (12%) 3 (7%) 3 (9%) 2 (9%)
18 (14%) 7 (17%) 5 (16%) 3 (13%)
68 (54%) 10 (24%)* 9 (28%)* 3 (13%)*
99 (79%) 23 (58%)* 17 (53%)* 11 (48%)*
24 (19%) 13 (33%) 10 (31%) 7 (30%)
43 (34%) 19 (45%) 15 (47%) 11 (48%)
21 (17%) 14 (33%)* 11 (34%)* 7 (30%)*
28 49* 48* 52*
7 (6%) 11 (28%)* 9 (28%)* 10 (43%)*
al score in the inventories.
Fig. 1. Distribution of patients according to the Mini International Neuropsychiatric Interview (MINI).
Fig. 2. Distribution of psychiatric diagnosis in patients with IDD according to the Mini International Neuropsychiatric Interview (MINI). +Presence of psychiatric diagnosis in
addition to IDD.
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patients without any psychiatric comorbidity.
3.4. IDD and epilepsy diagnosis according to ICD-10
No statistically signiﬁcant difference was found in the
frequency of IDD when comparing patients with simple focal
seizures (G40.1), secondarily generalized seizures (G40.2) and
generalized seizures (G40.3).
3.5. IDD, seizure control, and antidepressants
Fig. 3 illustrates the level of seizure control in the different
groups of patients according to psychiatric comorbidity and
presence of IDD.
Patients with IDD without MINI-veriﬁed psychiatric disorders
did not differ in seizure freedom when compared to patients with
no psychiatric disorder. The percentage of seizure free patients was
signiﬁcantly lower in patients with a psychiatric diagnosis
according to MINI, especially depression and anxiety. Treatment
with antidepressants was signiﬁcantly more common in the group
with IDD and additional MINI diagnosis.3.6. IDD and suicidality
Suicidality was found in 13 of the 169 patients (8%), and 11 of
the epilepsy patients with suicidality fulﬁlled the criteria for IDD.
Seven patients had low risk of suicidality; three had moderate risk
and three high risk. All patients with moderate or high risk of
suicidality were diagnosed with psychiatric comorbidities other
than IDD. We did not ﬁnd any association between speciﬁc
antiepileptic drugs and the presence of suicidality.
3.7. Well-being, quality of life and adverse effects to AEDs
As shown in Fig. 4 patients without psychiatric comorbidity had
the highest well-being and quality of life and the lowest level of
adverse effects. Patients with a psychiatric diagnosis according to
MINI had the lowest level of well-being and quality of life and the
highest level of side effects. In patients with only IDD but without
any MINI veriﬁed psychiatric comorbidity we found signiﬁcantly
higher level of well-being and quality of life and signiﬁcantly lower
level of adverse effects to AEDs when compared to patients with
IDD and MINI veriﬁed psychiatric disorders. When comparing
these patients to patients with normal screening, they had higher
Table 2
Patients without IDD, with IDD alone, and IDD in addition to MINI veriﬁed psychiatric disorders. n refers to the number of patients in each category with % in brackets.
No IDD Only IDD IDD + additional psychiatric disorder
Subjects, n 137 (81%) 13 (43%) 17 (57%)
Gender, female, n 60 (44%) 10 (83%)y 10 (58%)*
Age, mean years (SD) 55 (17.2) 48 (16.6) 46 (14.3)*,y
Epilepsy diagnosis, n
G40.2 94 (69%) 10 (77%) 12 (71%)
Other 43 (31%) 3 (23%) 5 (29%)
AEDs, n
Lamotrigin 105 (77%) 7 (54%) 8 (44%)*,y
Levetiracetam 27 (20%) 4 (31%) 6 (33)
Others 46 (34%) 5 (38%) 10 (55%)
AED poly-therapy, n 24 (18%) 4 (31%) 5 (29%)
Seizure free in the previous year, n 69 (50%) 7 (54%) 3 (18%)*,y
Adverse effects to AED according to LAEP (score range 20–80) 30 43y 53y
Treatment with antidepressants, n 9 (7%) 1 (8%) 8 (47%)*,y
* Statistically signiﬁcant difference (P < 0.05) between patients with IDD and additional psychiatric disorder compared with patients with only IDD.
y Statistically signiﬁcant difference (P < 0.05) between the subgroup and patients without IDD.
Fig. 3. Proportion of patients that were seizure-free in the previous year in various groups: n indicates the total number of patients in each group. *Statistically signiﬁcant
difference (P < 0.05) when compared with patients with normal screening.
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quality of life.
3.8. Reproducibility of IDDI
To assess the reproducibility of IDDI, patients with IDD were
asked to repeat the IDDI. Twenty-two patients with IDD repeated
the self-report inventory. The time interval between the ﬁrst and
the second IDDI varied from 4 to 11 weeks. Only 11 of 22 patients
(50%) fulﬁlled the diagnostic criteria for IDD the second time. Seven
of the 13 patients with IDD as the only psychiatric disorder
repeated the IDDI, and only 2 fulﬁlled the diagnostic criteria for
IDD the second time, making the reproducibility of IDDI even lower
(29%) in this group.
4. Discussion
In this study, we ﬁnd that IDD is diagnosed with IDDI in 19% of
epilepsy outpatients. The main ﬁnding is that the reproducibility of
IDDI is only 50%. Thus, IDD seems to be the most prevalentneuropsychiatric syndrome in epilepsy but it cannot be diagnosed
in a reproducible way.
Our ﬁnding that IDD occurs with the same frequency in focal and
generalized epilepsy is in line with recent publications.15,16With the
Portuguese version of IDDI, 51% of the patients in tertiary epilepsy
centers had IDD, and as in our study two thirds of the patients with
IDD were females.17 Our ﬁnding of 19% of patients with IDD using
IDDI matched the ﬁnding by Mula et al.6 (17%). The distinction
between interictal dysphoric disorder and periictal dysphoric
symptoms has been emphasized,18 and we therefore chose to study
epilepsy outpatients to eliminate too much inﬂuence of periictal
symptoms in patients admitted due to seizures.
Given the large variation in frequency of IDD and its
considerable overlap with other psychiatric disorders in epilepsy
patients it is tempting to speculate whether IDD exists as a
nosological entity. IDDI identiﬁes epilepsy patients with a
remarkable female preponderance, and the group of IDD patients
have increased occurrence of antiepileptic side effects, reduced
quality of life, and reduced well-being compared to epilepsy
patients without psychiatric comorbidity.
Fig. 4. Well-being (WHO-5 range 0–100), quality of life (QOLIE-31 range 11–73), and adverse effects to AEDs (LAEP range 20–80) in patients with epilepsy. *Statistically
signiﬁcant difference (P < 0.05) when compared to patients with normal screening. yStatistically signiﬁcant (P < 0.05) difference when compared to patients with IDD
without MINI veriﬁed psychiatric diagnosis.
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sole psychiatric comorbidity. Depression was the commonest
companion, occurring in 27% of our IDD patients, whereas Mula
et al.6 found more than 40% of the IDD patients to have a current
depression. They found depression to be the commonest psychi-
atric comorbidity in epilepsy. We found dysthymia and anxiety
disorders coupled to IDD in frequencies matching those published
by Mula et al.6 As epilepsy patients with depression and IDD have
many symptoms in common it could be speculated whether IDD is
a speciﬁc disorder. Mula et al. argue that IDD is qualitatively
different from depression. Especially the so called speciﬁc IDD
symptoms paroxysmal irritability and euphoric moods are
assumed to be characteristic for IDD and not for depression.6
Consequently, we would expect paroxysmal irritability and
euphoria to occur more frequently in patient with isolated IDD.
However, only 10% of the patients in the current study with IDD
had euphoria. Paroxysmal irritability was found in a higher
frequency with IDD and additional psychiatric disorders compared
to IDD alone. The data indicate that paroxysmal irritability and to asmaller extent euphoria is connected with psychiatric comorbidity
more generally, and not IDD speciﬁcally.
We found that quality of life was signiﬁcantly lower in patients
with IDD and other psychiatric comorbidity both when compared
to IDD patients without other psychiatric comorbidity and patients
without IDD. A signiﬁcantly poorer seizure control in the group of
patients with IDD in addition to other psychiatric comorbidity
could be of importance. Likewise, almost half of the patients in the
latter group were in treatment with antidepressants when
entering the study compared to only 8% of the patients who had
IDD as the only psychiatric comorbidity. Thus, the health status for
the epilepsy patients with IDD seems to depend on other
psychiatric comorbidity more than on IDD.
It is remarkable that 37% of the epilepsy patients with IDD have
suicidality as assessed by the MINI, whereas 8% of all participating
epilepsy patients displayed suicidality. The severity of suicidality is
more dependent on the presence of depression or other psychiatric
comorbidity according to MINI than IDD. Epilepsy patients have an
increased risk of committing suicide even in the absence of
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patients with epilepsy and comorbid psychiatric disease.19
Recently, Hesdorffer et al.20 found that epilepsy is associated with
an increased risk of psychiatric disorders and suicide even before
the epilepsy diagnosis disorders. The explanation could be
common underlying pathophysiological mechanisms.
IDD is not limited to epilepsy. Migraine patients fulﬁll the
criteria for IDD to the same extent as epilepsy patients.6 At present,
we do not know whether patients with chronic diseases affecting
other organ systems could have IDD.
If we assumed that IDD exists as a nosological entity in epilepsy,
how could we diagnose it? In this study we have used IDDI as
published in English1 and translated it into Danish according to
published methods.8 We found a frequency of IDD (19%) very
comparable with the frequency published for the English version of
IDDI.6 However, only 11 of 22 patients (50%) fulﬁlled the criteria for
the diagnosis IDD the second time. Since the time frame for IDD
symptoms is 12 months, a change in condition over a few weeks
cannot be the explanation for the low degree of reproducibility.
Language problems, cognitive problems or lack of compliance are
unlikely explanations. In our opinion, the most likely explanation is
that the inventory testing for IDD is complicated and difﬁcult to ﬁll
out in a reproducible way. We also base this opinion on our own
work with the translation of IDD from English to Danish. For each of
the 8 symptoms of IDD there are four levels of questions. The ﬁrst
level regards presence or absence of a symptom, the second level the
occurrence of the symptom in time with four possible answers; the
third level the severity of the symptom with four possible answers
and ﬁnally the impairment due to the symptom with four possible
answers. We imagine that many epilepsy patients would have
difﬁculties ﬁlling out the inventory, especially when considering the
long time frame of 12 months. In the hands of our epilepsy patients
IDDI does not have the necessary reliability. Consequently there
seems to be a need for prospective studies to clarify if IDD exists, and
if so, to devise a reliable diagnostic tool.
The major limitation in our study is that patients with normal
screening did not undergo MINI. Consequently, we cannot exclude a
present psychiatric comorbidity in these patients. However IDDI
cannot be validated by the MINI, since it is not a DSM-IV diagnosis
and therefore this limitation does not change our conclusion.
Furthermore, our study is limited by the number of patients
included, which results in problems with subgroup analysis, for
example when assessing the presence of psychiatric comorbidity in
different groups of epilepsy patients. A large number of patients (see
patient ﬂowchart in supplementary information) were excluded
from our study because of severe mental retardation of cognitive
dysfunction. This introduces a selection bias, since many of these
patients are probably in higher risk of suffering from psychiatric
comorbidities.
5. Conclusion
IDDI identiﬁes 19% of the epilepsy outpatients as having IDD.
Two thirds are female, and they are more likely to have reduced
quality of life and well-being and increased risk of AED side effects
and suicidality. However, more than half of these patients fulﬁll the
DSM-IV criteria for depression, dysthymia, or an anxiety disorder.
Furthermore, the seizure control and the use of antidepressants is
the same among IDD patients as in patients without psychiatric
comorbidity. The supposed IDD speciﬁc symptom euphoria was
only found in 10% of the IDD patients. Paroxysmal irritability
seemed more prominent in patients with IDD and additional
psychiatric comorbidities as opposed to patients with only IDD.
Other studies show that IDD is not speciﬁc for epilepsy. IDDI in the
Danish version had a reproducibility of only 50%. Based on theseresults the existence of IDD as a nosological entity is doubtful, and
reliable tools for its identiﬁcation are lacking.
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